A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients

A. Jacome, S. Navarro, J. A. Casado, P. Rio, L. Madero, J. Estella, J. Sevilla, I. Badell, J. J. Ortega, T. Olivé, H. Hanenberg, J. C. Segovia, Juan A. Bueren

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an inherited DNA repair disorder characterized by genetic instability of cells lacking a functional FA/BRCA pathway. Previous studies have shown that in vitro stimulation of bone marrow cells (BMCs) from FA mice promotes apoptosis, reduces the reconstitution ability of the stem cells, and induces myelodysplasia and myeloid leukemia upon reinfusion of the cells. This suggests the convenience of adapting standard protocols of gene therapy to FA. Here we show that the reserve of BM progenitors in FA patients is generally below 20% of normal values. Because this reduced reserve could activate the cycling of BM progenitors, we developed a simplified protocol to transduce BMCs from FA patients with gammaretroviral vectors. We demonstrate that a short in vitro manipulation (12-24 hr) of fresh mononuclear BMCs is sufficient to transduce 42% of hematopoietic progenitors from FA-A patients, in the absence of in vitro prestimulation. When FA/VCA-expressing vectors were used, this simple procedure reversed the phenotype of the BM progenitors from these patients. We propose that our approach will be more efficient and safer compared with standard gene therapy protocols for FA.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalHuman Gene Therapy
Volume17
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Fanconi Anemia
Genetic Therapy
Safety
Bone Marrow Cells
Inborn Genetic Diseases
Myeloid Leukemia
DNA Repair
Reference Values
Stem Cells
Apoptosis
Phenotype

ASJC Scopus subject areas

  • Genetics

Cite this

Jacome, A., Navarro, S., Casado, J. A., Rio, P., Madero, L., Estella, J., ... Bueren, J. A. (2006). A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. Human Gene Therapy, 17(2), 245-250. https://doi.org/10.1089/hum.2006.17.245

A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. / Jacome, A.; Navarro, S.; Casado, J. A.; Rio, P.; Madero, L.; Estella, J.; Sevilla, J.; Badell, I.; Ortega, J. J.; Olivé, T.; Hanenberg, H.; Segovia, J. C.; Bueren, Juan A.

In: Human Gene Therapy, Vol. 17, No. 2, 02.2006, p. 245-250.

Research output: Contribution to journalArticle

Jacome, A, Navarro, S, Casado, JA, Rio, P, Madero, L, Estella, J, Sevilla, J, Badell, I, Ortega, JJ, Olivé, T, Hanenberg, H, Segovia, JC & Bueren, JA 2006, 'A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients', Human Gene Therapy, vol. 17, no. 2, pp. 245-250. https://doi.org/10.1089/hum.2006.17.245
Jacome, A. ; Navarro, S. ; Casado, J. A. ; Rio, P. ; Madero, L. ; Estella, J. ; Sevilla, J. ; Badell, I. ; Ortega, J. J. ; Olivé, T. ; Hanenberg, H. ; Segovia, J. C. ; Bueren, Juan A. / A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. In: Human Gene Therapy. 2006 ; Vol. 17, No. 2. pp. 245-250.
@article{39ae6def57724ce283ea504ae7854c8b,
title = "A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients",
abstract = "Fanconi anemia (FA) is an inherited DNA repair disorder characterized by genetic instability of cells lacking a functional FA/BRCA pathway. Previous studies have shown that in vitro stimulation of bone marrow cells (BMCs) from FA mice promotes apoptosis, reduces the reconstitution ability of the stem cells, and induces myelodysplasia and myeloid leukemia upon reinfusion of the cells. This suggests the convenience of adapting standard protocols of gene therapy to FA. Here we show that the reserve of BM progenitors in FA patients is generally below 20{\%} of normal values. Because this reduced reserve could activate the cycling of BM progenitors, we developed a simplified protocol to transduce BMCs from FA patients with gammaretroviral vectors. We demonstrate that a short in vitro manipulation (12-24 hr) of fresh mononuclear BMCs is sufficient to transduce 42{\%} of hematopoietic progenitors from FA-A patients, in the absence of in vitro prestimulation. When FA/VCA-expressing vectors were used, this simple procedure reversed the phenotype of the BM progenitors from these patients. We propose that our approach will be more efficient and safer compared with standard gene therapy protocols for FA.",
author = "A. Jacome and S. Navarro and Casado, {J. A.} and P. Rio and L. Madero and J. Estella and J. Sevilla and I. Badell and Ortega, {J. J.} and T. Oliv{\'e} and H. Hanenberg and Segovia, {J. C.} and Bueren, {Juan A.}",
year = "2006",
month = "2",
doi = "10.1089/hum.2006.17.245",
language = "English (US)",
volume = "17",
pages = "245--250",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients

AU - Jacome, A.

AU - Navarro, S.

AU - Casado, J. A.

AU - Rio, P.

AU - Madero, L.

AU - Estella, J.

AU - Sevilla, J.

AU - Badell, I.

AU - Ortega, J. J.

AU - Olivé, T.

AU - Hanenberg, H.

AU - Segovia, J. C.

AU - Bueren, Juan A.

PY - 2006/2

Y1 - 2006/2

N2 - Fanconi anemia (FA) is an inherited DNA repair disorder characterized by genetic instability of cells lacking a functional FA/BRCA pathway. Previous studies have shown that in vitro stimulation of bone marrow cells (BMCs) from FA mice promotes apoptosis, reduces the reconstitution ability of the stem cells, and induces myelodysplasia and myeloid leukemia upon reinfusion of the cells. This suggests the convenience of adapting standard protocols of gene therapy to FA. Here we show that the reserve of BM progenitors in FA patients is generally below 20% of normal values. Because this reduced reserve could activate the cycling of BM progenitors, we developed a simplified protocol to transduce BMCs from FA patients with gammaretroviral vectors. We demonstrate that a short in vitro manipulation (12-24 hr) of fresh mononuclear BMCs is sufficient to transduce 42% of hematopoietic progenitors from FA-A patients, in the absence of in vitro prestimulation. When FA/VCA-expressing vectors were used, this simple procedure reversed the phenotype of the BM progenitors from these patients. We propose that our approach will be more efficient and safer compared with standard gene therapy protocols for FA.

AB - Fanconi anemia (FA) is an inherited DNA repair disorder characterized by genetic instability of cells lacking a functional FA/BRCA pathway. Previous studies have shown that in vitro stimulation of bone marrow cells (BMCs) from FA mice promotes apoptosis, reduces the reconstitution ability of the stem cells, and induces myelodysplasia and myeloid leukemia upon reinfusion of the cells. This suggests the convenience of adapting standard protocols of gene therapy to FA. Here we show that the reserve of BM progenitors in FA patients is generally below 20% of normal values. Because this reduced reserve could activate the cycling of BM progenitors, we developed a simplified protocol to transduce BMCs from FA patients with gammaretroviral vectors. We demonstrate that a short in vitro manipulation (12-24 hr) of fresh mononuclear BMCs is sufficient to transduce 42% of hematopoietic progenitors from FA-A patients, in the absence of in vitro prestimulation. When FA/VCA-expressing vectors were used, this simple procedure reversed the phenotype of the BM progenitors from these patients. We propose that our approach will be more efficient and safer compared with standard gene therapy protocols for FA.

UR - http://www.scopus.com/inward/record.url?scp=32944469302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944469302&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.245

DO - 10.1089/hum.2006.17.245

M3 - Article

C2 - 16454658

AN - SCOPUS:32944469302

VL - 17

SP - 245

EP - 250

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -